相关临床试验
0
0 进行中
药物批准
309
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- The US Court of Appeals for the Third Circuit affirmed summary judgment in favor of Sun Pharma and its subsidiaries, substantially closing the decade-old Lipitor antitrust litigation. - The appellate court upheld the denial of class certification to plaintiffs, significantly limiting their future legal recourse and reducing financial risks. - The litigation centered on a 2008 patent settlement with Pfizer that plaintiffs alleged unlawfully delayed generic competition for Lipitor (atorvastatin). - The resolution removes a major legal overhang, allowing Sun Pharma to focus on its core business, including its US$11.75 billion acquisition of Organon.
- Philogen has resubmitted an updated Marketing Authorization Application to the EMA for Nidlegy in locally advanced, fully resectable melanoma. - The updated dossier includes extended median follow-up data of 33 months from the pivotal Phase III PIVOTAL study, up from 21 months in the prior submission. - Nidlegy demonstrated a 41% lower risk of relapse or death compared with surgery alone, with a favorable safety profile of primarily low-grade local adverse events. - Sun Pharma holds exclusive commercialization rights across Europe, Australia, and New Zealand under a 50:50 profit-sharing agreement with Philogen.
- Samsung Bioepis and Organon announced expansion of their commercialization agreement to bring a fourth biosimilar product to Australia via Organon ANZ, deepening a partnership now in its thirteenth year. - Australia's biosimilar market reached approximately USD $906 million in 2025 and is forecast to reach USD $6.7 billion by 2034, yet anti-TNF biosimilar uptake in retail pharmacy sits at just 36 percent, well below the OECD average of 67 percent. - The 2026–27 Federal Budget included a commitment to reviewing whether biosimilars should become the default for new prescriptions, a reform the GBMA estimates could free up to $1.5 billion in PBS headroom over five years. - Sun Pharma's pending $11.75 billion acquisition of Organon, expected to close in early 2027, would make the combined entity the seventh-largest seller of biosimilars globally.
- Sol-Gel Technologies received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044, significantly strengthening the commercial potential of their lead candidate. - The company completed an oversubscribed underwritten offering raising gross proceeds of approximately $33.1 million from leading healthcare specialist investors to fund continued development of SGT-610. - The pivotal Phase 3 clinical trial of SGT-610 for Gorlin syndrome remains on track with top-line results anticipated in the fourth quarter of 2026. - Sol-Gel expanded its global commercialization strategy by signing an exclusive license agreement with Sun Pharmaceutical Industries for TWYNEO® in India, adding to eight previous agreements covering multiple territories.
- Sun Pharmaceutical Industries, India's largest drugmaker, is evaluating the acquisition of US-based Organon for approximately $10 billion, marking what would be the largest cross-border pharmaceutical acquisition in Indian history. - The potential deal would give Sun Pharma significant access to women's health products and biosimilars, including Organon's top-selling contraceptive Nexplanon and a robust biosimilar pipeline worth $660 million in annual sales. - Organon, spun out from Merck in 2021 with $9.5 billion in inherited debt, has faced financial challenges and leadership changes, making it an attractive turnaround opportunity for Sun Pharma's proven acquisition strategy.
- Sun Pharma Advanced Research Company (SPARC) is implementing a major restructuring to achieve $10 million in annual cost savings while managing $46 million in debt and consolidating operations in Vadodara. - The company is reducing its workforce by 40% to 246 employees by FY27 and cutting R&D spending from $20.4 million to $14.3 million in FY25 while focusing on high-value oncology and immunology assets. - Lead oncology candidate SBO-154, an anti-MUC1-SEA antibody drug conjugate, is advancing through Phase 1a dose escalation targeting multiple cancer types with maximum tolerated dose readout expected by Q4 2026. - Immunology asset SCD-153, a first-in-class topical itaconate prodrug for alopecia areata and vitiligo, completed Phase 1b cohort 1 with topline results anticipated in Q4 2026.
- Taro Pharmaceutical Industries, a wholly-owned subsidiary of Sun Pharma, initiated a Class II nationwide recall of 17,664 units of Ciclopirox Shampoo on December 9, 2024. - The antifungal medication used to treat seborrheic dermatitis was recalled due to failed impurity and degradation specifications identified during manufacturing quality control. - The USFDA classified this as a Class II recall, indicating potential for temporary or medically reversible health consequences with minimal likelihood of serious adverse outcomes. - This recall highlights ongoing quality control challenges for Indian pharmaceutical companies, which supply four out of ten prescriptions filled in the US market.
- AstraZeneca Pharma India and Sun Pharmaceutical Industries have formed a brand partnership to distribute sodium zirconium cyclosilicate (SZC) for hyperkalaemia treatment across India. - The companies will market the drug under different brand names, with AstraZeneca retaining intellectual property rights while Sun Pharma leverages its extensive distribution network. - Hyperkalaemia affects up to 50% of chronic kidney disease patients and 42% of heart failure patients, with mortality rates of 22.2% reported in India. - The partnership aims to address the significant disease burden by expanding access to this rapid and effective treatment option for managing elevated potassium levels.
- Fortress Biotech achieved a 20.5% increase in net revenue to $17.6 million in Q3 2025, driven by strong performance from its dermatology products portfolio. - The company completed strategic exits with Sun Pharma acquiring Checkpoint Therapeutics for ~$28 million upfront to Fortress, plus potential additional payments and royalties. - Dotinurad, a next-generation URAT1 inhibitor for gout treatment, advanced into two Phase 3 trials following Crystalys Therapeutics' $205 million Series A financing. - Journey Medical's rosacea treatment Emrosi demonstrated statistical superiority over existing therapies in pooled Phase 3 analysis, with expanded payer coverage reaching over 100 million lives.
- Orexo will host a seminar at Nordic Life Science Days on October 13 to share insights from its recent patent victory against Sun Pharmaceutical Industries in December 2024. - The Swedish pharmaceutical company has successfully defended its intellectual property against major generic challengers including Actavis/Teva in 2018 and Sun Pharmaceutical in 2024. - The session will provide pharmaceutical companies with strategies for building robust patent defenses before entering the US market, focusing on protecting innovations like Zubsolv for opioid dependence. - Industry experts from Potter Clarkson LLP and Steptoe LLP will join Orexo executives to discuss how companies can successfully defend against generic litigation challenges.
